Nishioka K
Japanese Red Cross Central Blood Center, Tokyo.
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:152-5. doi: 10.1007/BF02779287.
Because of the high incidence of non-A non-B post transfusion hepatitis and its relation to hepatocellular carcinoma, HCV antibody screening for blood transfusion was begun in November 1989. Seroepidemiological studies revealed the great magnitude of HCV infection in acute hepatitis, chronic hepatitis, liver cirrhosis and hepatocellular carcinoma in Japan. Approximately 1.6 million HCV antibody-positive persons are now in Japan. Major routes of infection are considered to be horizontal blood borne infection in the past and blood transfusion.
由于非甲非乙型输血后肝炎的高发病率及其与肝细胞癌的关系,1989年11月开始对输血进行丙型肝炎病毒(HCV)抗体筛查。血清流行病学研究显示,在日本,急性肝炎、慢性肝炎、肝硬化和肝细胞癌患者中HCV感染情况严重。目前日本约有160万HCV抗体阳性者。主要感染途径被认为是过去的水平血液传播感染以及输血。